Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Pitressin

(Vasopressin)

ApprovedSmall molecule

AAultman Health Foundation

Vasopressin is used to treat abnormally low blood pressure, control bleeding from the digestive tract, and manage a condition where the body doesn't produce enough of its natural water-regulating hormone.[2] Pitressin is currently approved and in use across 30 indications[4].[1]

Pitressin is one of 474 small molecule programs targeting Benign Muscle Neoplasm. It is currently in Approved.

30

Indications

55

Total Trials

14

Active Trials

473

Competitors

4

FDA Applications

NDA/BLA/ANDA regulatory filings

16

Patents

Pipeline

Status by Indication[4][1]

Indication

Benign Muscle NeoplasmApproved

EnuresisActive, not recruiting

Sudden Cardiac ArrestApproved

Uterine LeiomyomaActive, not recruiting

Liver TransplantActive, not recruiting

Diabetes InsipidusActive, not recruiting

ShockApproved

PolyuriaActive, not recruiting

SepsisActive, not recruiting

Acute Lung InjuryApproved

Benign Muscle NeoplasmApproved

Approved

EnuresisApproved

Active, not recruiting

Sudden Cardiac ArrestApproved

Approved

Uterine LeiomyomaPreclinical

Active, not recruiting

Liver TransplantPreclinical

Active, not recruiting

Diabetes InsipidusApproved

Active, not recruiting

ShockApproved

Approved

PolyuriaApproved

Active, not recruiting

SepsisApproved

Active, not recruiting

Acute Lung InjuryApproved

Approved

Showing 10 of 29 indications

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Pitressin

AAultman Health Foundation

Ozempic

Resotran

Inapsine

Jazz Pharmaceuticals

Depakote

Ibrance

Lunesta

Akero Therapeutics

Persantine

Boehringer Ingelheim

Luvox

SSolvay Pharmaceuticals

Catapres

Boehringer Ingelheim

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Intensive Care Unit

NCT02118467

Q1 2028

Phase 2Recruiting

Trauma

NCT05958342

Clinical

Trials by Indication[1]

Septic Shock11 trials

NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock

Withdrawn·UUniversity of Arkansas·Phase 4·NCT02454348

Efficacy and Safety of Vasopressin Versus Terlipressin as a Second Vasopressor in Critically Ill Cirrhotics With Septic Shock- the VITEL-C Trial

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05315557·100 enrolled

Comparison of Vasopressin and Other Pressors in Septic Shock

Completed·UUniversité de Sherbrooke·Phase 2/3·NCT00269685·20 enrolled

Show 8 more trials

Angiotensin II vs. Vasopressin in Septic Shock

Withdrawn·UUniversity of New Mexico·Phase 4·NCT05193370

Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients

Completed·IInstituto do Cancer do Estado de São Paulo·Phase 3·NCT01718613·250 enrolled

Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator

Terminated·TThe Cleveland Clinic··NCT06426407·2 enrolled

Continuous Infusion of Terlipressin in Septic Shock

Completed·UUniversity of Roma La Sapienza·Phase 2·NCT00481572·45 enrolled

The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock

Recruiting·KKing's College Hospital NHS Trust·N/A·NCT06234592·45 enrolled

Discontinuation Order of Vasopressors in Septic Shock

Terminated·SSamsung Medical Center·N/A·NCT01493102·78 enrolled

Hemodynamic Effects of Vasopressin in Early Septic Shock Stage

Completed·FFederal University of São Paulo·N/A·NCT02053675·18 enrolled

Vasopressin for Septic Shock Pragmatic Trial

Completed·IIntermountain Health Care, Inc.·Approved·NCT06217562·3,959 enrolled

Tranexamic Acid3 trials

Topical Tranexamic Acid Plus Perivascular Vasopressin at the Time of Abdominal Myomectomy

Unknown status·—·N/A·NCT03880045·100 enrolled

Tranexamic Acid vs Vasopressin in Placenta Previa Trial

Not yet recruiting·—·Phase 3·NCT07423156·58 enrolled

Tranexamic Acid in Vaginal Reconstructive Surgery

Withdrawn·TThe University of Texas Medical Branch, Galveston·Phase 4·NCT06419075

Trauma3 trials

AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock

Completed·UUniversity of Pennsylvania·Phase 2·NCT01611935·101 enrolled

Low Dose Vasopressin in Traumatic Shock

Terminated·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00420407·81 enrolled

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Recruiting·JJason Sperry·Phase 2·NCT05958342·1,050 enrolled

Attention3 trials

Differential Effects of Vasopressin and Oxytocin on Attention Control

Completed·UUniversity of Electronic Science and Technology of China·N/A·NCT04715737·160 enrolled

The Effects of Vasopressin on Attention Control

Completed·UUniversity of Electronic Science and Technology of China·N/A·NCT04493554·89 enrolled

The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study

Recruiting·UUniversity of Electronic Science and Technology of China·N/A·NCT06329037·80 enrolled

Cardiac Surgery2 trials

Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery

Recruiting·TThomas Jefferson University·Phase 4·NCT04602767·300 enrolled

Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery

Withdrawn·UUniversity of Sao Paulo·Phase 2/3·NCT03483753

29 more indications

ESS2 trials

Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study

Recruiting·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT04053478·144 enrolled

Vasopressin Versus Epinephrine in Myomectomy

Completed·—·Phase 3·NCT01861015·60 enrolled

After Cardiac Surgery2 trials

Vasopressin Versus Norepinephrine for the Management of Shock After Cardiac Surgery

Unknown status·UUniversity of Sao Paulo·Phase 3·NCT01505231·300 enrolled

Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery

Recruiting·UUniversity of Sao Paulo·Phase 4·NCT06934798·350 enrolled

Hysterectomy2 trials

Vasopressin Versus Tranexamic Acid for Control of Blood Loss Related to Abdominal Hysterectomy

Not yet recruiting·—·Phase 4·NCT06290596·387 enrolled

Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial

Completed·—·Phase 4·NCT00799292·58 enrolled

Autism2 trials

The Role of Vasopressin in the Social Deficits of Autism

Completed·SStanford University·Phase 2·NCT01962870·68 enrolled

Intranasal Vasopressin Treatment in Children With Autism

Completed·SStanford University·Phase 2/3·NCT03204786·157 enrolled

Blood Pressure1 trial

Decision Support for Intraoperative Low Blood Pressure

Completed·VVanderbilt University Medical Center·N/A·NCT02726620·22,435 enrolled

Autism Spectrum Disorder1 trial

Brain Imaging Study of Adults With Autism Spectrum Disorders

Completed·NNational Institute of Mental Health (NIMH)·Phase 1·NCT01093768·38 enrolled

Liver Transplant1 trial

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

Completed·MMedical University of South Carolina·N/A·NCT00886262·18 enrolled

Hemorrhagic Shock1 trial

Vasopressin in Traumatic Hemorrhagic Shock Study

Completed·VVolker Wenzel·Phase 2/3·NCT00379522·64 enrolled

CABG1 trial

The Effect of Vasopressors on Cerebral Oxygentaion During Off Pump CABG

Completed·SSeoul National University Hospital·N/A·NCT04214145·90 enrolled

Randomized Controlled Trial1 trial

Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial

Completed·—·Phase 4·NCT01393704·152 enrolled

Hemodynamic1 trial

The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology

Completed·SStanford University·Phase 1·NCT04463394·28 enrolled

Hysteroscopic Myomectomy1 trial

Vasopressin Injection Versus Misoprostol During Hysteroscopic Myomectomy In Reducing Blood Loss And Operation Time.

Completed·ZZagazig University·Phase 2/3·NCT03930069·40 enrolled

Bleeding1 trial

Methods Decreasing Bleeding in Open Myomectomy

Unknown status·—·Phase 4·NCT05806307·105 enrolled

Cardiac Arrest1 trial

Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest

Completed·SSingapore General Hospital·Phase 3·NCT00358579·727 enrolled

Acute Kidney Injury1 trial

Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU

Recruiting·HHospital do Coracao·Phase 2·NCT06547892·60 enrolled

Kidney Failure1 trial

Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation

Active, not recruiting·—·Phase 3·NCT05568160·840 enrolled

Neonatal1 trial

Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation

Recruiting·UUniversity of Alberta·Phase 1·NCT05738148·20 enrolled

Concentration1 trial

Comparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy

Completed·SSeoul National University Hospital·N/A·NCT04874246·39 enrolled

Pediatric1 trial

Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation

Completed·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT00628550·130 enrolled

Surgery1 trial

The Effect of Restrictive Fluid and Vasopressin During Surgery of Burn Patients

Unknown status·—·N/A·NCT03590873·158 enrolled

Fontan1 trial

Use of Vasopressin Following the Fontan Operation

Completed·WWake Forest University Health Sciences·Phase 2/3·NCT02975999·12 enrolled

Shock1 trial

Registry of Patients in Shock Treated With Vasopressin

Recruiting·HHospital Universitario 12 de Octubre··NCT06422975·500 enrolled

Intensive Care Unit1 trial

Vasoactive Drugs in Intensive Care Unit

Recruiting·UUniversity of Chicago·Phase 4·NCT02118467·836 enrolled

Pulmonary Hypertension1 trial

Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension

Terminated·UUniversity of Alberta·Phase 2·NCT01370096·3 enrolled

Misoprostol1 trial

Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy

Completed·UUniversity Hospital of the West Indies·Phase 4·NCT01700478·45 enrolled

Oxytocin1 trial

Effects of Oxytocin and Vasopressin on Moral Decision Making

Completed·UUniversity of Electronic Science and Technology of China·N/A·NCT04890470·180 enrolled

Oral1 trial

Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

Recruiting·UUniversity of Electronic Science and Technology of China·N/A·NCT06329063·80 enrolled

Cardiac Disease1 trial

Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients: a Comparative-effectiveness Quality Project

Completed·TThe Cleveland Clinic·Phase 3·NCT04501861·153 enrolled

Unspecified1 trial

Neurobiological Bases of Paternal Nurturance

Completed·—·N/A·NCT02223429·35 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 17, 2014

VASOSTRICT

NDA NDA204485

Aug 3, 2020

VASOPRESSIN

NDA NDA212593

Sep 29, 2023

VASOPRESSIN IN SODIUM CHLORIDE 0.9%

NDA NDA217569

Jul 11, 2024

VASOPRESSIN IN SODIUM CHLORIDE 0.9%

NDA NDA217766

Sources

References

[1]
ClinicalTrials.gov — 55 trial records for Vasopressin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Pitressin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Vasopressin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Vasopressin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217766). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Pitressin. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Aultman Health Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vasopressin Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAultman Health Foundation

Patent Landscape[6]

Patent Cliff

Jan 30, 2035

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9750785Jan 30, 2035

9744209Jan 30, 2035

9937223Jan 30, 2035

9744239Jan 30, 2035

10010575Jan 30, 2035

11 more patents

9981006Jan 30, 2035

9974827Jan 30, 2035

9968649Jan 30, 2035

9962422Jan 30, 2035

9925234Jan 30, 2035

9925233Jan 30, 2035

9687526Jan 30, 2035

12186362Jan 30, 2035

9919026Jan 30, 2035

9375478Jan 30, 2035

12447190Sep 27, 2044

Related News